Crispr Therapeutics shares tumble after significant earnings miss
West Pharmaceutical (NYSE:WST) received a reiterated Overweight rating and $325.00 price target from KeyBanc, aligning with the broader analyst consensus of "Strong Buy." The research firm cited significant growth opportunities for West as a supplier of elastomer components for injectable GLP-1 weight loss and diabetes medications. According to InvestingPro data, seven analysts have recently revised their earnings estimates upward, with price targets ranging from $245 to $325.
KeyBanc notes that West is involved with nearly 100% of injectable GLP-1 products and is positioned to benefit from recent capacity expansions by manufacturers like Eli Lilly (NYSE:LLY) and Thermo Fisher Scientific (NYSE:TMO). The firm highlighted West’s strategically located Kinston, NC facility and expanded contract manufacturing operations in Grand Rapids and Dublin as key assets supporting this growth. The company maintains strong financial health with an "Overall Good" rating from InvestingPro, supported by a healthy current ratio of 2.77 and moderate debt levels.
The GLP-1 market is experiencing rapid expansion, with sales growing 73% in 2024 and expected to reach over $150 billion by 2030, according to KeyBanc’s analysis. This growth trajectory suggests GLP-1 medications will soon match and eventually far surpass the peak COVID-19 vaccine market, which reached approximately $82 billion.
KeyBanc’s analysis indicates GLP-1 medications could represent approximately 19% of the estimated $889 billion combined biologic and GLP-1 sales by 2030, up from about 9% in 2023. This substantial market shift creates significant long-term revenue opportunities for component suppliers like West Pharmaceutical.
Recent capacity investments by major pharmaceutical companies, including Eli Lilly’s $2 billion facility and Novo Nordisk (NYSE:NVO)’s planned expansions through 2027-2029, further signal strong industry confidence in sustained GLP-1 demand that will benefit component suppliers like West Pharmaceutical. With trailing twelve-month revenues of $2.9 billion and a robust gross profit margin of 34.5%, West demonstrates strong operational efficiency. Discover more detailed financial metrics and 12 additional ProTips with InvestingPro’s comprehensive analysis tools.
In other recent news, West Pharmaceutical Services Inc . reported strong financial results for the first quarter of 2025, with earnings per share (EPS) of $1.45, surpassing the forecast of $1.23. The company’s revenue also exceeded expectations, reaching $698 million compared to the anticipated $684.94 million. These results highlight the company’s effective market execution and operational efficiency. In corporate governance developments, West Pharmaceutical announced the results of its 2025 Annual Meeting of Shareholders, where all nominated directors were elected, and key proposals such as executive compensation and amendments to the Articles of Incorporation were approved. The shareholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year 2025. Additionally, the company is seeing a strategic shift with leadership changes, including the appointment of a new Senior Vice President. West Pharmaceutical maintains a positive outlook, forecasting full-year 2025 net sales between $2.945 billion and $2.975 billion, with expected organic sales growth of 2-3%. Analyst firm KeyBanc noted the company’s focus on maintaining operational efficiency amid these transitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.